AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC
Status:
Not yet recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
The investigators want to evaluated the Efficay and Satety of PD-1/VEGR bispecific antibodies
(AK112) plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC who Failed from
First-Line Standard Treatment.